Keywords: sanofi, files, extended, eloxatin, use, french, drugmaker
Sanofi files for extended Eloxatin use
Article | 26 January 2004
French drugmaker Sanofi-Synthelabo has submitted a supplemental New Drug Application with the US Food and Drug Administration and an extension ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Pfizer to split-off remaining 80% interest in Zoetis
